FRIDAY, Feb. 17, 2023 (HealthDay News) For patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 16 to 18 in San Francisco. Neeraj
Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
THURSDAY, Feb. 16, 2023 (HealthDay News) Plant-based diets are associated with a reduced risk for prostate cancer (PC) progression and recurrence, according to a study presented at the American